Related Experiment Video

Updated: Sep 10, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Sotorasib provides a durable response in high-grade metastatic ovarian serous adenocarcinoma harbouring KRAS G12C

Hariharasudan Mani1, Suresh Nair2

  • 1Lehigh Valley Topper Cancer Institute, Allentown, Pennsylvania, USA harimani2017@gmail.com.

BMJ Case Reports
|August 27, 2025
PubMed

Insights

This case study shows a rare Kristen rat sarcoma viral oncogene homologue (KRAS) G12C mutation in ovarian cancer. A patient with metastatic ovarian cancer experienced a durable response to the KRAS G12C inhibitor sotorasib.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Metastatic ovarian cancer with recurrent disease after multiple treatments has a poor prognosis.
  • The Kristen rat sarcoma viral oncogene homologue (KRAS) G12C mutation is uncommon in ovarian cancers.
  • Currently, no targeted KRAS G12C treatments are approved for ovarian cancer.

Purpose of the Study:

  • To report a case of metastatic ovarian serous adenocarcinoma.
  • To evaluate the efficacy of a KRAS G12C inhibitor in a patient with a rare KRAS G12C mutation in ovarian cancer.

Main Methods:

  • A single-case study design.
  • Treatment with sotorasib, a KRAS G12C inhibitor, at a reduced dose (240 mg daily).
  • Long-term follow-up for response assessment.

Main Results:

  • The patient, a female in her late 70s, showed an excellent and durable response to sotorasib.
  • The response has been ongoing for over 26 months.
  • The treatment was administered at a reduced oral daily dose of 240 mg.

Conclusions:

  • KRAS G12C can be a driver mutation in a subset of ovarian cancer patients.
  • Targeted therapy with KRAS G12C inhibitors may be a viable option for specific ovarian cancer subgroups.
  • This case highlights the potential of sotorasib in treating rare KRAS G12C-mutated ovarian cancers.
Keywords:
Gynecological cancerTherapeutic indications

More Related Videos

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K